Mark Lansdell

In this engaging discussion, Mark Lansdell, Director at Evaluate, shares his expertise on China's rapid rise in research and development. He highlights the transformation of China’s market from generics to innovative drug development fueled by a skilled workforce and supportive policies. Lansdell also explores the increase in licensing deals between Chinese and Western companies, addressing the complexities of early-stage partnerships and the challenges of using Chinese clinical trial data globally. His insights reveal the competitive dynamics reshaping the life sciences landscape.